Immunization Newsbriefs (c) Copyright Information Inc., Bethesda, MD. Brought to you by the National Network for Immunization Information (NNii). Visit NNii's new website at http://www.immunizationinfo.org.
------------------------------------------------------------
September 13, 2002
INTERNATIONAL IMMUNIZATION NEWS
"HIV Vaccine Optimism in Barcelona"
LANCET Infectious Diseases (infection.thelancet.com) (09/02) Vol. 2, No. 9,; Spencer, Stuart
A feeling that the development of effective therapeutic HIV vaccines is not far off permeated the recent AIDS conference in Barcelona, Spain. One research team indicated that it developed a vaccine that both lowered viral load and stimulated a T-helper immune response that recognized HIV. One vaccine that targets gp120 is being tested in two Phase III trials. The use of HIV genes in naked DNA together with modified genes was presented at the conference as a promising adjuvant. The main downfall of the vaccine is that the results are variable. Any vaccine with a lower confidence limit for effectiveness of over 30 percent will be considered by the FDA.
ALL INFORMATION, DATA, AND
MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS
OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR
LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND
COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH
YOUR HEALTH CARE PROVIDER.